Skip to content


Spravato (esketamine) is a small molecule pharmaceutical. Esketamine was first approved as Spravato on 2019-03-05. It is used to treat treatment-resistant depressive disorder in the USA. It has been approved in Europe to treat depressive disorder. Spravato's patents are valid until 2035-09-10 (FDA).
Trade Name Spravato
Common Name Esketamine
Indication depressive disorder, treatment-resistant depressive disorder
Drug Class Nmda receptor antagonists; Antidepressants; General anesthetics; Dissociative hallucinogens; Analgesics
Get full access now